Tuesday 26 September

07.30-09.00             EDUCATION TRACK 3 : Above and below the diaphragm

CREATORS: Arne Neyrinck, Leuven, Belgium and Annemarie Weissenbacher, Oxford, United Kingdom

CHAIRS: Jim Egan, Dublin, Ireland and Annemarie Weissenbacher, Oxford, United Kingdom

Lectures :

  • Old and new listing criteria for  lung and heart transplantation
    John Dark, Newcastle, United Kingdom
  • Old and new listing criteria for liver, pancreas and intestinal transplantation
    Peter Friend, Oxford, United Kingdom
  • How do factors from above the diaphragm impact on the outcome of organ Tx below the diaphragm?
    Stephan Eschertzhuber, Innsbruck, Austria
  • Combined transplanted patients - Which organ drives the immunosuppressive regimen?
    Nassim Kamar, Toulouse, France

 

07.30-09.00             EDUCATION TRACK 4 : Pathophysiology and endpoints on tolerance

CREATORS: Mark Dahlke, Regensburg, Germany and Henri Leuvenink, Groningen, The Netherlands

CHAIRS: Cristina Cuturi, Nantes, France and Nina Pilat, Vienna, Austria

Lectures :

  • Clinical tolerance studies
    Megan Sykes, New York, United States
  • Clinical tolerance endpoints/biomarkers
    Robert Lechler, London, United Kingdom
  • Macrophages and the induction of tolerance
    Jordi Orchando, New York, United States
  • Treg inducing allograft tolerance in human
    Giovanna Lombardi, London, United Kingdom

 

08.00-09.00             Full oral sessions

                                Brief oral sessions

 

09:10 - 10:40           STATE OF THE ART 4 | NEW CONCEPTS IN TRANSPLANT INFECTIOUS DISEASES: MICROBIOTA, AND BEYOND

CREATORS: Marina Berenguer, Valencia, Spain and Nicolas Mueller, Zurich, Switzerland

New genetic tools have allowed an unprecedented insight into the composition of our microbiota, and virome. first we explore the known role of the virome and microbiota specifically in transplantation. Potential clinical applications are discussed. The new anti-HCV drugs have made eradication of HCV a realistic goal in virtually all patients. We learn about the impact on transplantation on an individual and epidemiological level. And finally, the immunomodulatory role of viruses in transplantation are often mentioned – but does this concept hold up? A critical appraisal of the concept of the indirect effects of viruses is presented. How important is a complete control of viral replication?

CHAIRS: Marisa Alegre and Marina Berenguer, Valencia, Spain

Lectures :

  • Transkingdom interplay - the complex interactive world of the microbiome
    Dave Wang, St. Louis, United States
  • Knowledge and clinical applications of microbiota in transplantation
    Frederick Bushman, Philadelphia, United States
  • Viruses and recipient immune response: relevant crosstalk in transplantation
    Oriol Manuel, Lausanne, Switzerland
  • The impact of HCV treatment on liver transplantation
    Michael R.Charlton, Salt Lake City, United States

 

09:10 - 10:40           STATE OF THE ART 5 | CELL THERAPY IN CLINICAL TRIALS

CREATORS: Marc Dahlke, Regensburg, Germany and Pietro Cippà, Zurich, Switzerland

Cell therapy offers great hope for being a suitable adjunct to conventional immunosuppression with all its downsights, however major issues emerged in the long translation process towards the clinic. How can technical and regulatory hurdles be overcome within a realistic time frame? Will cell therapy be commercially interesting and will its implementation relaunch solid organ transplantation? Experts share their experience and explain what we might expect from cell therapy for tomorrow and in 10 years.

CHAIRS: Marc Dahlke, Regensburg, Germany and Thomas Wekerle, Vienna, Austria

Lectures :

  • Technical and regulatory issues. From the idea to the clinical application
    Marlies Reinders, Leiden, The Netherlands
  • Sharing clinical experience. What can we learn from hematologists?
    Francesco Dazzi, London, United Kingdom
  • Translational studies. Why do we need cell therapy if we cannot avoid severe immunosuppression?
    Suzanne T. Ilstad, Louisville, United States
  • The future: Clinical applications of stem cells, transplantation vs. regeneration? Clinical applications of stem cells, transplantation vs. regeneration?
    Alan Trouson, Clayton, Australia

 

09:10 - 10:40           STATE OF THE ART 6 | ONE FOR ALL OR ALL FOR ONE; GETTING AWAY FROM PROTOCOLIZED MEDICINE

CREATORS: Georg Boehmig, Vienna, Austria and Nicolas Mueller, Zurich, Switzerland

The ultimate goal of transplantation is long-term survival with a well-functioning graft. Operationalization of post-transplant care with protocols based on evidence from clinical trials has had an important impact on the overall quality after transplantation. It is increasingly recognized though that the ‘one size fits all’ approach does not always optimally reflect the patient’s individual need. Hence, the concept of personalized medicine is on everyone's lips. This session aims to confront the reality by asking the following questions, focusing on four important topics in the field.

CHAIRS: Georg Boehmig, Vienna, Austria and Nicolas Mueller, Zurich, Switzerland

Lectures :

  • Is transplantation ready for systems medicine?
    Rainer Oberbauer, Vienna, Austria
  • Individualized antimicrobial prophylaxis
    Jay Alan Fishman, Boston, United States
  • Phenotypic diversity of rejection and allograft dyfunction
    Phil Halloran, Edmonton, Canada
  • Tailored immunosuppression
    Christian Hugo, Dresden, Germany

 

11.10-12.40             BIG BANG 3 | INNOVATION IN IMMUNOMEDICATION: THE MODERN PROMETHEUS

CREATORS: Josep Maria Grinyó, Barcelona, Spain and Olivier Thaunat, Lyon, France

Putting their steps in those of Dr Frankenstein, scientists have started stitching disparate biological pieces to create new therapeutic opportunities. Far from Sci-Fi fantasies, these therapeutic innovations have already shown promising results in the field of cancer therapy. Their potential to revolutionize solid organ transplantation will be scrutinized during this Big Bang session.

 

 

11.10-12.40             Asia leading the way

                                Full oral sessions

                                Elevator Pitch sessions

 

13.00-14.00             Corporate Parallel lunch Symposia

                                Brief oral sessions

 

13.00-14.00             Rising Stars on stage

  • Presentation fellowship Study Results 1
  • Presentation fellowship Study Results 2
  • TED Talk: ‘Life changing events’
  • TED Talk: ‘A very personal story on success and failure’

 

14:05-15:35             PLENARY SESSION  3 | INNOVATION UNDER PRESSURE: TRANSPLANT PATIENT CARE IN 2020

CREATORS: Marina Berenguer, Valencia, Spain and Antonio Roman, Barcelona, Spain

Health care is undergoing a fundamental change. While new fields in medicine are emerging and short-term results are satisfactory, long-term care of patients after transplantation is more complex and challanging then ever. While novel technologies may help to effectiverly monitor patients after transplantation, novel structures and business models are warranted to ensure optimal patient care and advancement of the field.

CHAIRS: John Forsythe, Edinburgh, United Kingdom and Christophe Legendre, Paris, France

Lectures :

  • Prospects and pushbacks in hand face uterus abdominal wall penile transplant and others
    Wei-Ping Andrew Lee, Baltimore, United States
  • Beyond survival: quality of life after transplantation
    Lianne Singer, Toronto, Canada
  • New tech for new patients: digital communication and self-monitoring
    Giral Magali, Nantes, France
  • KEYNOTE New models for patient care: wish for what you care for
    Marcel Levi, London, United Kingdom

 

16.00-17.00             BIG BANG 4 | AGEING AND IMMORTALITY

CREATORS: Maarten Naesens, Leuven, Belgium and Olivier Thaunat, Lyon, France

In this session, we discuss the changing demographics of donors and recipients, and the impact on transplantation (organ quality, ischemia-reperfusion injury and immunosenescence). Transplant allocation organisations are implementing age-matching in their allocation procedures. The benefits and the potential drawbacks of these important changes are discussed. In addition, the biology of ageing, and the concept of accelerated ageing after transplantation is covered in BB4, with illustrations of the great relevance of ageing for the future of patients and grafts. Finally, we evaluate innovative ways to halt or slow down these ageing processes, and discover the clues to immortality.

CHAIR : Maarten Naesens, Leuven, Belgium

Lectures:

  • Older graft, older recipients, young ideas
    Stefan Tullius, Boston, United States
  • Accelerated ageing after transplantation
    Peter Stenvinkel, Stockholm, Sweden
  • Halting aging: the science of rejuvenation
    Brian Kennedy, Novato, United States

 

16.00-17.00             The Devil's Advocate ( Clinical )

                                Brief oral sessions

 

17.00-18.30             Corporate Plenary/Parallel Symposium

                                Full oral sessions

 

18.30-19.30             ESOT General Assembly

                                Elevator Pitch sessions

                                Brief oral sessions